Real-life efficacy and safety of nintedanib in systemic sclerosis-interstitial lung disease: data from an Italian multicentre study. Issue 1 (22nd February 2023)

• Record Type: Journal Article
• Authors: Campochiaro, Corrado; De Luca, Giacomo; Lazzaroni, Maria-Grazia; Armentaro, Giuseppe; Spinella, Amelia; Vigone, Barbara; Ruaro, Barbara; Stanziola, Anna; Benfaremo, Devis; De Lorenzis, Enrico; Moccaldi, Beatrice; Bosello, Silvia Laura; Cuomo, Giovanna; Beretta, Lorenzo; Zanatta, Elisabetta; Giuggioli, Dilia; Del Papa, Nicoletta; Airo, Paolo; Confalonieri, Marco; Moroncini, Gianluca; Dagna, Lorenzo; Matucci-Cerinic, Marco
• Is Part Of: RMD open. Volume 9:Issue 1(2023)
• Publication Date: 2023-02-22
• Subjects: scleroderma, systemic -- pulmonary fibrosis -- biological therapy -- therapeutics; Musculoskeletal system -- Diseases -- Periodicals; Rheumatism -- Periodicals; 616.7005
• DOI: 10.1136/rmdopen-2022-002850
• Languages: English
• ISSNs: 2056-5933

Abstract

Abstract : Introduction: Nintedanib (NTD) has been shown to be effective in systemic sclerosis (SSc)-interstitial lung disease (ILD). Here we describe the efficacy and safety of NTD in a real-life setting. Methods: Patients with SSc-ILD treated with NTD were retrospectively evaluated at 12 months prior to NTD introduction; at baseline and at 12 months after NTD introduction. The following parameters were recorded: SSc clinical features, NTD tolerability, pulmonary function tests and modified Rodnan skin score (mRSS). Results: 90 patients with SSc-ILD (65% female, mean age 57.6±13.4 years, mean disease duration 8.8±7.6 years) were identified. The majority were positive for anti-topoisomerase I (75%) and 77 (85%) patients were on immunosuppressants. A significant decline in %predicted forced vital capacity (%pFVC) in the 12 months prior to NTD introduction was observed in 60%. At 12 months after NTD introduction, follow-up data were available for 40 (44%) patients and they showed a stabilisation in %pFVC (64±14 to 62±19, p=0.416). The percentage of patients with significant lung progression at 12 months was significantly lower compared with the previous 12 months (60% vs 17.5%, p=0.007). No significant mRSS change was observed. Gastrointestinal (GI) side effects were recorded in 35 (39%) patients. After a mean time of 3.6±3.1 months, NTD was maintained after dose adjustment in 23 (25%) patients. In nine (10%) patients, NTD was stopped after a median time of 4.5 (1–6) months. During the follow-up, four patients died. Conclusions: In a real-life clinical scenario, NTD, in combination with immunosuppressants, may stabilise lung function. GI side effects are frequent and NTD dose adjustment may be necessary to retain the drug in patients with SSc-ILD.